Navigation Links
New medical weapons to protect against anthrax attacks
Date:6/23/2010

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

In the article, Dimitrios Bouzianas notes that several existing antibiotics are available to combat an anthrax infection. However, the emergence of artificially engineered B. anthracis strains, resistant to multiple antibiotics (including the front-line agents ciprofloxacin, doxycycline, and β-lactam antibiotics) has prompted researchers to pursue additional therapeutic options. Such alternatives include small molecules and antibodies against toxins that the lethal bacteria secrete. Passive immunization using a polyclonal or a high-affinity monoclonal antibody may offer adjunctive value to antibiotic therapy. Today's drug arsenal has another weakness: no medications available to fight the dangerous toxin that can circulate in a person's blood when antibiotic treatment begins after the disease has taken hold. Therefore, there is an urgent need for the discovery of antitoxin agents that would be effective at the end stage of anthrax.

Bouzianas describes promising new treatments now in various stages of development. They include a new genre of anthrax vaccines that would be more effective and yet require fewer doses than current vaccines. Among them: A long-sought inhalable vaccine that people might self-administer without a needle. Importantly, this powered vaccine would not require refrigeration and would have a long shelf life ideal for the strategic drug stockpiles kept on hand for rapid distribution in case of national emergencies. Also on the horizon: New antibiotics that are less likely to encounter resistance and medicines that can block the effects of anthrax toxin. Because anthrax is rare as a natural disease in humans, the development of new treatment modalities is seriously hampered by the difficulty in demonstrating their effectiveness in humans.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New medical weapons to protect against anthrax attacks
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... 2017 , ... Executive search firm, Slone Partners, announces the ... is a distinguished life sciences expert with a proven track record in strategic ... wide range of services related to laboratory testing and analysis for the pharmaceutical, ...
(Date:3/27/2017)... , March 27, 2017 Cousins Properties (NYSE: ... the world,s leading biotechnology companies, has signed a 10-year, approximately ... Class A office asset located in the Westshore submarket of ... are thrilled that Amgen has chosen Corporate Center for their ... Larry Gellerstedt , president and chief executive officer of Cousins ...
(Date:3/27/2017)... , March 27, 2017  The global market ... 2016, according to a new report from Kalorama ... testing is performed to evaluate disease progression, monitor ... among other reasons.  The healthcare market research firm,s ... , provides an overview of the medical laboratory ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to announce ... by The Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses ... trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also will ...
Breaking Biology Technology: